Coherus Oncology, Inc. (formerly Coherus BioSciences) is a commercial-stage immuno-oncology company. Its approved product LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, is FDA-approved for nasopharyngeal carcinoma (NPC). Its pipeline includes casdozokitug (CHS-388), an IL-27 antagonist antibody for hepatocellular carcinoma, and tagmokitug (CHS-114), a CCR8-targeting antibody for head and neck, GI, and colorectal cancers. The company commercializes LOQTORZI in the U.S. and holds global rights to its pipeline candidates.
Q2 FY2026 — expected 2026-09-05
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001104659-26-025308 | EDGAR | 91K words |
| 2025-03-17 | 2024-12-31 | 0001558370-25-003126 | EDGAR | 109K words |
| 2024-03-15 | 2023-12-31 | 0001558370-24-003436 | EDGAR | 108K words |
| 2023-03-06 | 2022-12-31 | 0001558370-23-002917 | EDGAR | — |
| 2022-02-23 | 2021-12-31 | 0001558370-22-001764 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001558370-21-001829 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007416 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001564590-19-005470 | EDGAR | — |
| 2018-03-08 | 2017-12-31 | 0001564590-18-004947 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001564590-17-004176 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001104659-26-091262 | EDGAR | 55K words |
| 2025-11-06 | 2025-09-30 | 0001104659-25-107852 | EDGAR | 60K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010803 | EDGAR | 61K words |
| 2025-05-12 | 2025-03-31 | 0001558370-25-007418 | EDGAR | 59K words |
| 2024-11-06 | 2024-09-30 | 0001558370-24-014648 | EDGAR | 74K words |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011629 | EDGAR | 73K words |
| 2024-05-09 | 2024-03-31 | 0001558370-24-007641 | EDGAR | 69K words |
| 2023-11-06 | 2023-09-30 | 0001558370-23-017779 | EDGAR | 76K words |
| 2023-08-02 | 2023-06-30 | 0001558370-23-012915 | EDGAR | 70K words |
| 2023-05-08 | 2023-03-31 | 0001558370-23-008529 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016850 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012251 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-28 | 0001104659-26-103316 | EDGAR | 26K words |
| 2026-08-17 | 0001104659-26-097951 | EDGAR | 11K words |
| 2026-08-17 | 0001104659-26-097949 | EDGAR | 34K words |
| 2026-08-05 | 0001104659-26-091188 | EDGAR | 4K words |
| 2026-03-09 | 0001104659-26-025293 | EDGAR | 5K words |
| 2026-02-17 | 0001104659-26-016378 | EDGAR | 22K words |
| 2026-02-04 | 0001104659-26-010065 | EDGAR | 1K words |
| 2026-01-23 | 0001104659-26-006307 | EDGAR | 1K words |
| 2026-01-13 | 0001104659-26-003117 | EDGAR | 1K words |
| 2025-11-13 | 0001104659-25-111484 | EDGAR | 40K words |
285 total filings indexed. 253 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001512762 |
| Ticker | CHRS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.coherus.com |
| Listed | 2014-11-06 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CHRS (~200 tokens, structured JSON with cryptographic provenance)